4D Molecular Therapeutics (FDMT) Enterprise Value (2019 - 2025)
Historic Enterprise Value for 4D Molecular Therapeutics (FDMT) over the last 7 years, with Q3 2025 value amounting to -$305.1 million.
- 4D Molecular Therapeutics' Enterprise Value rose 3921.74% to -$305.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$305.1 million, marking a year-over-year increase of 3921.74%. This contributed to the annual value of -$424.9 million for FY2024, which is 4740.8% down from last year.
- Latest data reveals that 4D Molecular Therapeutics reported Enterprise Value of -$305.1 million as of Q3 2025, which was up 3921.74% from -$293.2 million recorded in Q2 2025.
- In the past 5 years, 4D Molecular Therapeutics' Enterprise Value ranged from a high of -$161.7 million in Q3 2021 and a low of -$541.9 million during Q2 2024
- In the last 5 years, 4D Molecular Therapeutics' Enterprise Value had a median value of -$288.2 million in 2023 and averaged -$308.7 million.
- Per our database at Business Quant, 4D Molecular Therapeutics' Enterprise Value crashed by 16235.99% in 2024 and then surged by 4589.41% in 2025.
- Quarter analysis of 5 years shows 4D Molecular Therapeutics' Enterprise Value stood at -$247.8 million in 2021, then increased by 13.81% to -$213.6 million in 2022, then crashed by 34.97% to -$288.2 million in 2023, then plummeted by 47.41% to -$424.9 million in 2024, then rose by 28.2% to -$305.1 million in 2025.
- Its Enterprise Value was -$305.1 million in Q3 2025, compared to -$293.2 million in Q2 2025 and -$321.4 million in Q1 2025.